Dailypharm Live Search Close

Trodelvy can be prescribed at general hospitals in KOR

By Eo, Yun-Ho | translator Kim, Jung-Ju

24.01.06 05:50:30

가나다라 0
Passes DCs of AMC…applies for landing in SNUH and other medical institutions

Reimbursement guidelines set during the CDDC meeting last November… are expected to be reviewed by DREC soon


Another new antibody-drug conjugate drug for breast cancer, ‘Trodelvy,’ can now be prescribed at general

According to industry sources, Gilead Science Korea’s triple-negative breast cancer (TNBC) treatment ‘Trodelvy (sacituzumab govitecan-hziy)’ has recently passed the drug committee review of Seoul Asan Medical Center.

In addition, landing procedures for the drug are also underway at tertiary hospitals such as Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.

Trodelvy passed the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in November last year and is currently awaiting review by the Drug

Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)